Financial results - RUBICON PHARMACEUTICALS SRL

Financial Summary - Rubicon Pharmaceuticals Srl
Unique identification code: 30099764
Registration number: J2012000996351
Nace: 4646
Sales - Ron
17.588.772
Net Profit - Ron
869.312
Employees
19
Open Account
Company Rubicon Pharmaceuticals Srl with Fiscal Code 30099764 recorded a turnover of 2024 of 17.588.772, with a net profit of 869.312 and having an average number of employees of 19. The company operates in the field of Comerţ cu ridicata al produselor farmaceutice și medicale having the NACE code 4646.
Sales - Ron

Sales, Profit, Employees, Total Income, Financial Results - Rubicon Pharmaceuticals Srl

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Sales - EUR 7.280.517 14.079.284 13.597.941 15.162.100 13.827.399 10.512.304 12.581.898 14.146.567 16.381.921 17.588.772
Total Income - EUR 7.301.443 14.115.775 13.645.883 15.196.238 13.883.954 10.538.951 12.600.796 14.168.860 16.403.588 17.686.139
Total Expenses - EUR 6.789.945 13.179.216 12.866.010 14.092.349 13.115.446 10.234.422 11.985.212 13.300.036 15.560.461 16.673.034
Gross Profit/Loss - EUR 511.497 936.559 779.873 1.103.890 768.508 304.528 615.584 868.824 843.127 1.013.106
Net Profit/Loss - EUR 430.051 791.555 615.598 919.849 643.877 249.381 513.990 730.188 708.990 869.312
Employees 9 10 14 16 16 18 18 18 19 19
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded. In the last year of activity, the sales increased by 8.0%, from 16.381.921 euro in the year 2023, to 17.588.772 euro in 2024. The Net Profit increased by 164.284 euro, from 708.990 euro in 2023, to 869.312 in the last year.
Sales - Ron
Net Profit - Ron
Employees

Check the financial reports for the company - Rubicon Pharmaceuticals Srl

Rating financiar

Financial Rating -
RUBICON PHARMACEUTICALS SRL

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Financial Rating
Limite de plata

Payment Limits -
Rubicon Pharmaceuticals Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Rubicon Pharmaceuticals Srl

It determines the risk of insolvency based on the submitted accounting balance.

Insolvency Probability
Rapoarte financiare

Financial Reports -
Rubicon Pharmaceuticals Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Rubicon Pharmaceuticals Srl - CUI 30099764

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Fixed Assets 193.365 233.787 1.109.422 1.138.610 2.103.679 2.025.802 1.849.338 1.855.146 1.856.908 1.907.036
Current Assets 1.950.139 2.479.280 2.561.034 4.060.626 2.439.290 4.316.185 4.301.293 4.493.357 6.587.073 5.919.081
Inventories 177.649 445.032 1.391.748 1.862.922 676.476 2.450.141 1.233.177 1.759.670 2.979.610 2.347.981
Receivables 1.504.355 1.902.684 999.280 2.063.841 1.656.813 1.609.438 2.947.198 2.690.049 3.566.650 3.410.850
Cash 268.135 131.563 170.006 133.863 106.000 256.605 120.917 43.638 40.814 160.250
Shareholders Funds 430.510 1.063.747 878.289 1.537.137 1.677.859 1.663.792 1.877.215 1.664.640 2.365.987 2.676.389
Social Capital 450 222.677 218.909 214.892 632.191 826.942 808.604 811.112 808.653 804.133
Debts 1.715.258 1.651.136 2.794.385 3.664.079 2.868.144 4.684.692 4.277.777 4.689.333 6.087.594 5.176.567
Income in Advance 0 0 0 0 0 0 0 0 0 0
Exchange rate - RON 4.9743 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445
Main CAEN "4646 - 4646"
CAEN Financial Year 4646
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 5.919.081 euro in 2024 which includes Inventories of 2.347.981 euro, Receivables of 3.410.850 euro and cash availability of 160.250 euro.
The company's Equity was valued at 2.676.389 euro, while total Liabilities amounted to 5.176.567 euro. Equity increased by 323.625 euro, from 2.365.987 euro in 2023, to 2.676.389 in 2024.

Risk Reports Prices

Reviews - Rubicon Pharmaceuticals Srl

Comments - Rubicon Pharmaceuticals Srl

Similar services useful for checking companies and business development.

SellNet

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Databases

Export in excel files the data of the companies selected according to the desired criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.